Results of the double-blinded and initial open-label phases of the ELECT Study demonstrate the effectiveness of lanreotide in controlling diarrhea and flushing in patients with NETs presenting with carcinoid syndrome.
Development of carcinoid syndrome has a profound effect on cost of care for patients with neuroendocrine tumors (NETs).
Patients who receieved lanreotide depot had a significantly lower percentage of days when rescue octreotide was used compared with placebo.
Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|